New drug MK-8189 tested for safety in bipolar patients
NCT ID NCT06273774
First seen May 04, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This early-stage study tested the safety of a new drug called MK-8189 (elpipodect) in 34 adults with stable bipolar I disorder. Participants took multiple doses of the drug, and researchers monitored for side effects. The study did not test whether the drug works; it only looked at safety and how the body processes the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta Center for Medical Research ( Site 0001)
Atlanta, Georgia, 30331, United States
-
Hassman Research Institute Marlton Site ( Site 0006)
Marlton, New Jersey, 08053, United States
-
Woodland International Research Group-Clinical Research ( Site 0009)
Little Rock, Arkansas, 72211, United States
Conditions
Explore the condition pages connected to this study.